作者: W. French Anderson , Frederick L. Hall , Li Li , Hongjun Peng , Peng X. Liu
DOI:
关键词: Genetic enhancement 、 Ophthalmology 、 Phototherapeutic keratectomy 、 Cornea 、 Corneal Haze 、 Medicine 、 In vivo 、 Photorefractive keratectomy 、 Viral vector 、 Eye drop 、 Pathology
摘要: PURPOSE To determine the in vivo efficacy and safety of a retroviral vector bearing an antiproliferative dominant negative mutant cyclin G1 (dnG1) construct, when used for prevention corneal haze after phototherapeutic keratectomy (PTK). METHODS For studies, 6-mm-diameter, 150-microm-deep transepithelial PTK, performed with clinical 193-nm ArF excimer laser (VISX Star2, Santa Clara, CA) was on left eyes 20 adult New Zealand White rabbits. The surgically altered were subsequently treated eye drops containing: dnG1 construct (dnG1; n = 7), control (null vector) only neomycin resistance, neo(r), gene (n or antisense (aG1) 6). time closure epithelial defect monitored daily fluorescein staining. Corneal evaluated before surgery at 2, 3, 4 weeks surgery, digital imaging system. Biodistribution studies detection potential dissemination to nontarget organs conducted by PCR-based assay. RESULTS re-epithelialization rate similar among treatment groups, complete 72 hours (P > 0.05). Significant developed null aG1 vector-treated groups